DiaMedica Therapeutics Net Income
| DMAC Stock | USD 7.95 0.28 3.40% |
As of the 27th of February, DiaMedica Therapeutics shows the Mean Deviation of 2.8, downside deviation of 3.66, and Semi Deviation of 3.53. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
DiaMedica Therapeutics Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -22 M | -20.9 M | |
| Net Loss | -22 M | -20.9 M | |
| Net Loss | -12.2 M | -11.6 M | |
| Net Loss | (0.54) | (0.57) | |
| Net Income Per E B T | 1.15 | 1.12 |
DiaMedica | Net Income | Build AI portfolio with DiaMedica Stock |
Analyzing DiaMedica Therapeutics's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing DiaMedica Therapeutics's current valuation and future prospects.
Latest DiaMedica Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of DiaMedica Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in DiaMedica Therapeutics financial statement analysis. It represents the amount of money remaining after all of DiaMedica Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is DiaMedica Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DiaMedica Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.44 M) | 10 Years Trend |
|
Net Income |
| Timeline |
DiaMedica Net Income Regression Statistics
| Arithmetic Mean | (10,595,376) | |
| Coefficient Of Variation | (70.90) | |
| Mean Deviation | 6,137,672 | |
| Median | (10,051,607) | |
| Standard Deviation | 7,512,571 | |
| Sample Variance | 56.4T | |
| Range | 23.8M | |
| R-Value | (0.85) | |
| Mean Square Error | 17T | |
| R-Squared | 0.72 | |
| Significance | 0.000017 | |
| Slope | (1,260,857) | |
| Total Sum of Squares | 903T |
DiaMedica Net Income History
Other Fundumenentals of DiaMedica Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
DiaMedica Therapeutics Net Income component correlations
DiaMedica Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for DiaMedica Therapeutics is extremely important. It helps to project a fair market value of DiaMedica Stock properly, considering its historical fundamentals such as Net Income. Since DiaMedica Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DiaMedica Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DiaMedica Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
DiaMedica Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to DiaMedica Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of DiaMedica Therapeutics.
| 11/29/2025 |
| 02/27/2026 |
If you would invest 0.00 in DiaMedica Therapeutics on November 29, 2025 and sell it all today you would earn a total of 0.00 from holding DiaMedica Therapeutics or generate 0.0% return on investment in DiaMedica Therapeutics over 90 days. DiaMedica Therapeutics is related to or competes with Altimmune, Galectin Therapeutics, EnGene Holdings, Annexon, Alpha Tau, Frequency Therapeutics, and Design Therapeutics. DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney... More
DiaMedica Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure DiaMedica Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess DiaMedica Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.66 | |||
| Information Ratio | 0.012 | |||
| Maximum Drawdown | 24.12 | |||
| Value At Risk | (5.95) | |||
| Potential Upside | 7.41 |
DiaMedica Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for DiaMedica Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as DiaMedica Therapeutics' standard deviation. In reality, there are many statistical measures that can use DiaMedica Therapeutics historical prices to predict the future DiaMedica Therapeutics' volatility.| Risk Adjusted Performance | 0.0349 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0128 | |||
| Treynor Ratio | 0.06 |
DiaMedica Therapeutics February 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0349 | |||
| Market Risk Adjusted Performance | 0.07 | |||
| Mean Deviation | 2.8 | |||
| Semi Deviation | 3.53 | |||
| Downside Deviation | 3.66 | |||
| Coefficient Of Variation | 2850.16 | |||
| Standard Deviation | 3.9 | |||
| Variance | 15.19 | |||
| Information Ratio | 0.012 | |||
| Jensen Alpha | (0.04) | |||
| Total Risk Alpha | (0.28) | |||
| Sortino Ratio | 0.0128 | |||
| Treynor Ratio | 0.06 | |||
| Maximum Drawdown | 24.12 | |||
| Value At Risk | (5.95) | |||
| Potential Upside | 7.41 | |||
| Downside Variance | 13.4 | |||
| Semi Variance | 12.49 | |||
| Expected Short fall | (3.22) | |||
| Skewness | 0.2354 | |||
| Kurtosis | 1.75 |
DiaMedica Therapeutics Backtested Returns
At this point, DiaMedica Therapeutics is somewhat reliable. DiaMedica Therapeutics secures Sharpe Ratio (or Efficiency) of close to zero, which denotes the company had a close to zero % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for DiaMedica Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm DiaMedica Therapeutics' Downside Deviation of 3.66, semi deviation of 3.53, and Mean Deviation of 2.8 to check if the risk estimate we provide is consistent with the expected return of 0.0107%. The firm shows a Beta (market volatility) of 2.11, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DiaMedica Therapeutics will likely underperform. DiaMedica Therapeutics right now shows a risk of 3.52%. Please confirm DiaMedica Therapeutics mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and total risk alpha , to decide if DiaMedica Therapeutics will be following its price patterns.
Auto-correlation | 0.03 |
Virtually no predictability
DiaMedica Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between DiaMedica Therapeutics time series from 29th of November 2025 to 13th of January 2026 and 13th of January 2026 to 27th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of DiaMedica Therapeutics price movement. The serial correlation of 0.03 indicates that only 3.0% of current DiaMedica Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | -0.11 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
DiaMedica Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, DiaMedica Therapeutics reported net income of (24.44 Million). This is 107.16% lower than that of the Biotechnology sector and 134.9% lower than that of the Health Care industry. The net income for all United States stocks is 104.28% higher than that of the company.
DiaMedica Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DiaMedica Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DiaMedica Therapeutics could also be used in its relative valuation, which is a method of valuing DiaMedica Therapeutics by comparing valuation metrics of similar companies.DiaMedica Therapeutics is currently under evaluation in net income category among its peers.
DiaMedica Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of DiaMedica Therapeutics from analyzing DiaMedica Therapeutics' financial statements. These drivers represent accounts that assess DiaMedica Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of DiaMedica Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 159.0M | 77.5M | 41.8M | 219.4M | 252.3M | 132.5M | |
| Enterprise Value | 151.7M | 72.8M | 37.5M | 216.7M | 249.2M | 128.8M |
DiaMedica Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, DiaMedica Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to DiaMedica Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
DiaMedica Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in DiaMedica Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of DiaMedica Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing DiaMedica Therapeutics' value.| Shares | Advisor Group Holdings, Inc. | 144.3 K | Charles Schwab Investment Management Inc | 2025-06-30 | 79.6 K | Royal Bank Of Canada | 2025-06-30 | 77.1 K | Ronald Blue Trust, Inc. | 2025-06-30 | 69.1 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 61.7 K | Bank Of New York Mellon Corp | 2025-06-30 | 60.1 K | Perigon Wealth Management, Llc | 2025-06-30 | 53 K | Barclays Plc | 2025-06-30 | 48.8 K | Catalyst Financial Partners Llc | 2025-06-30 | 38.5 K | Cooperman Leon G | 2025-06-30 | 1.6 M | Vanguard Group Inc | 2025-06-30 | 1.5 M |
DiaMedica Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 373.55 M | ||||
| Shares Outstanding | 52.08 M | ||||
| Shares Owned By Insiders | 28.66 % | ||||
| Shares Owned By Institutions | 39.70 % | ||||
| Number Of Shares Shorted | 4.4 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 8.30 X | ||||
| EBITDA | (26.64 M) | ||||
| Net Income | (24.44 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Short Ratio | 19.26 X | ||||
| Earnings Per Share | (0.71) X | ||||
| Price To Earnings To Growth | (0.07) X | ||||
| Target Price | 15.5 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 428.6 M | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Working Capital | 39.22 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
| Net Asset | 46.34 M |
About DiaMedica Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could DiaMedica diversify its offerings? Factors like these will boost the valuation of DiaMedica Therapeutics. Projected growth potential of DiaMedica fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every DiaMedica Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between DiaMedica Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding DiaMedica Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, DiaMedica Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.